Coadministration of an oral contraceptive had no significant effect on the exposure of dolutegravir, ethinylestradiol (3% increase in AUC, 1% decrease in Cmax) or norgestromin (AUC and Cmax decreased by 2% and 11%). Dolutegravir had no pharmacodynamic effect on luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with dolutegravir.

Tivicay Summary of Product Characteristics, ViiV Healthcare, January 2017.  

 

In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of norgestimate. Coadministration of norgestimate (0.25 mg) and dolutegravir (50 mg twice daily) to 15 subjects decreased norgestromin Cmax, AUC and Ctrough by 11%, 2% and 7%, respectively.

 

HIV-negative women received ethinylestradiol/norgestimate (0.035/0.25 mg) with and without dolutegravir 50 mg twice daily. Coadministration had no effect (changes of 3% or less) on the AUC, Cmax and Ctrough of ethinylestradiol. AUC, Cmax and Ctrough of norelgestromin (the active metabolite of norgestimate) decreased by 2%, 11% and 7%, respectively. No effect on luteinising hormone, follicle stimulating hormone and progesterone was observed, suggesting that contraceptive efficacy should be maintained if coadministered with dolutegravir